MedTrace Logo

Clinical Study to Evaluate the RxSight Light Adjustable Lens With the Light Delivery Device in Subjects With Preoperative Corneal Astigmatism

NCT03771352 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2021-06-09

Study results available
· View outcomes & findings →

Summary

For patients undergoing cataract surgery, the purpose of this study is to evaluate a patient's far vision without glasses and quality of vision after implantation and UV treatment of the RxSight Light Adjustable Lens (RxLAL).Following completion of all light treatments, the patient's far vision without glasses and quality of vision will be assessed 6 months postoperatively.

Conditions

  • Cataract

Interventions

DEVICE

RxSight RxLAL

The patients will be assessed for 6 months

Sponsors & Collaborators

  • RxSight, Inc.

    lead INDUSTRY

Principal Investigators

  • Burkhard Dick, MD · University Eye Clinic- Bochum, Germany

  • Fritz Hengerer, MD · University Eye Clinic- Heidelberg, Germany

  • Sathish Srinivasan, MD · Ayrshire Eye Clinic and Laser Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-19
Primary Completion
2019-07-01
Completion
2020-07-01
FDA Device
Yes

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03771352 on ClinicalTrials.gov